Abivax enrols first participant in Phase IIb Crohn's disease drug trial - MSN

Topline Results from Phase 2b Clinical Trial of UBX1325 for DME Expected in Q1 2025

The phase 2b clinical trial (ASPIRE) for UBX1325, targeting diabetic macular edema (DME), is currently underway, with topline results anticipated in the first quarter of 2025.

Regeneron advances anticoagulant antibody pair to late-stage testing - FirstWord Pharma

AnaptysBio pulls out of eczema drug race after Phase II flop - FirstWord Pharma

CyanVac's Intranasal COVID-19 Vaccine Candidate, CVXGA, Enters Phase 2b Trial

CyanVac's CVXGA, an intranasal COVID-19 vaccine, has dosed its first participant in a Phase 2b clinical study.
The trial, supported by Project NextGen, will compare CVXGA to an FDA-approved mRNA vaccine targeting the Omicron KP.2 variant.

Patient dies in Neurogene's Phase I/II Rett syndrome trial - MSN

EnteroBiotix Completes Phase 2 Trial Recruitment of EBX-102-02 for Irritable Bowel Syndrome

EnteroBiotix has completed recruitment for its Phase 2 TrIuMPH trial, which is evaluating EBX-102-02 in 122 patients with moderate to severe irritable bowel syndrome (IBS).
The trial includes patients with both constipation-predominant IBS (IBS-C) and diarrhea-predominant IBS (IBS-D), with 62 and 60 participants respectively.

Otsuka reports data from Phase III Alzheimer's agitation trial - MSN

Abivax's Phase 2b Trial of Obefazimod for Crohn's Disease Enrolls First Patient

Abivax has initiated its Phase 2b ENHANCE-CD trial, with the first patient enrolled to evaluate obefazimod in Crohn's disease.
The trial is a multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of once-daily obefazimod in adults.

Autobahn Therapeutics Initiates Phase 2 Trial of ABX-002 for Major Depressive Disorder

Autobahn Therapeutics has commenced the AMPLIFY Phase 2 trial to evaluate ABX-002 as an adjunctive treatment for major depressive disorder (MDD).
The trial will enroll 230 adults with moderate-to-severe depression to assess the safety, tolerability, efficacy, and pharmacodynamic effects of ABX-002.

Abivax's Phase 3 ABTECT Trial for Ulcerative Colitis Reaches Enrollment Milestone

Abivax's Phase 3 ABTECT trial, evaluating obefazimod for ulcerative colitis, has surpassed 600 patients enrolled, marking a significant milestone.
The trial is on track to achieve full enrollment in early Q1 2025, reinforcing the company's timeline for this pivotal study.